Although the experiments in Li et al. focused on CRC, they support the rationale for emerging trials in which SHP2 allosteric inhibitors are used with immune checkpoint inhibitors for other, traditionally immunosuppressive tumor types. The gene discussed is PTPN11; the disease is neoplasm.